Diabetic Macular Edema News and Research

RSS
Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.
Factors predictive of successful DME treatment revealed

Factors predictive of successful DME treatment revealed

Ethypharm, Ampio enter definitive agreement to manufacture Zertane

Ethypharm, Ampio enter definitive agreement to manufacture Zertane

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

Lucentis receives FDA approval for treatment of diabetic macular edema

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron reports total revenues of $304 million for second quarter 2012

FDA clears pSivida's IND for injectable sustained-release micro-insert to treat posterior uveitis

FDA clears pSivida's IND for injectable sustained-release micro-insert to treat posterior uveitis

Ampio announces advancement of NCE001 to preclinical development

Ampio announces advancement of NCE001 to preclinical development

Enrollment complete in Lux Biosciences Luveniq Phase 3 study for non-infectious uveitis

Enrollment complete in Lux Biosciences Luveniq Phase 3 study for non-infectious uveitis

Ampio announces results from Optina trial on DME

Ampio announces results from Optina trial on DME

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Ampio’s CRO completes Optina clinical trial for DME

Ampio’s CRO completes Optina clinical trial for DME

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

IRIDEX launches non-invasive MicroPulse Laser Trabeculoplasty for glaucoma

IRIDEX launches non-invasive MicroPulse Laser Trabeculoplasty for glaucoma

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Australian TGA approves Bayer's EYLEA for treatment of wet AMD

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron reports total revenues of $123.0M for fourth quarter 2011

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema